Lilly to Present Phase 3 BRUIN CLL-321 Data for Non-Covalent BTK Inhibitor Jaypirca at ASH Annual Meeting
Eli Lilly
Global Pharmaceutical R&D and Production Company
On November 5, 2024, local time, Eli Lilly and Company announced that the research data of the non-covalent Bruton's tyrosine kinase (BTK) inhibitor pirtobrutinib (Jaypirca) will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held in San Diego from December 7 to 10. The drug had previously met its primary endpoint in the Phase 3 clinical trial BRUIN CLL-321.
Jaypirca is a highly selective non-covalent (reversible) inhibitor. It is used to treat adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior systemic therapies, including a BTK inhibitor, or adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously received at least two lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
Eli Lilly will report the results of the Phase 3 BRUIN CLL-321 study at ASH. The study is evaluating the efficacy of pirtobrutinib in combination with either idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have been previously treated with a BTK inhibitor.Eli Lilly's submission of the conference abstract used data from February 2024, and the presentation will use data from August 2024.
In addition, Eli Lilly will present a poster sharing the analysis of real-world data, including overall survival related to the treatment sequence for CLL/SLL patients, as well as preclinical data on a first-in-class B-cell activating factor receptor (BAFF)-RxCD3 bispecific antibody for treating certain B-cell malignancies.
- END -
References:
Eli Lilly and Company Official Website:
https://investor.lilly.com/news-releases/news-release-details/lilly-announces-details-presentations-2024-american-society-0
Dear readers, if you don't star the "Health Neighbor" official account, you will miss daily updates on life and health news. Star "Health Neighbor" and let's explore and exchange the mysteries of life science together!
Recommended Reading
Eating Some of "It" Every Day May Help Prevent Cancer!
FDA Approves New Drug for Rosacea Treatment
Review of Innovative Medical Devices in China for October
Review of FDA-Approved Drugs in October
Inject at Home in 15s! Eisai/Biogen Alzheimer's Therapy Submits Regulatory Application
*Disclaimer*
Companion focuses on introducing research progress, industry trends, exhibitions, and conferences in the biopharmaceutical field.
This article is for informational exchange purposes only and does not represent the platform's position.
This article is intended for healthcare professionals to use as a learning reference only, and is not responsible for diagnosing diseases, providing prescriptions, etc.;
This article only provides an introduction to drugs related to healthcare, not a recommendation for treatment plans (if involved), and does not constitute any investment advice or suggestions. Please refer to official/company announcements for accuracy.
If there are any copyright issues involved, please contact us in a timely manner, and we will remove or otherwise handle them.